Feb 11, 2020
Overall Share of Ocrevus Remains Stable Among Recent New Start Patients, Yet Genentech's Efforts to Increase First-Line Use Appears to be Paying Off in the Dominant Relapsing-Remitting Multiple Sclerosis Subgroup
Feb 06, 2020
EMD Serono Receives Positive Recommendation for MAVENCLAD® (cladribine tablets) for the treatment of Relapsing-Remitting Multiple Sclerosis from the Institut national d'excellence en santé et en services sociaux (INESSS)
Jan 28, 2020
Harvard Professor Francisco Quintana Wins 2019 Barancik Prize for Innovation in MS Research
Jan 23, 2020
Multiple Sclerosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027
Jan 09, 2020
Clene Nanomedicine Announces First Patient Dosed in the REPAIR-MS Clinical Trial for the Treatment of Multiple Sclerosis with Lead Nanocatalytic Therapeutic, CNM-Au8
Jan 07, 2020
Clinical Trial of Autologous Hematopoietic Stem Cell Transplantation versus Best Available Therapy for Multiple Sclerosis (BEAT-MS) Begins Enrollment
Dec 19, 2019
MSAA Announces New Chairperson of Healthcare Advisory Council
Dec 10, 2019
EMD Serono and the pan-Canadian Pharmaceutical Alliance Complete Negotiations for MAVENCLAD® (cladribine tablets) for the treatment of Relapsing-Remitting Multiple Sclerosis
Dec 05, 2019
Accelerated Cure Project for Multiple Sclerosis Announces Leadership Changes
Dec 04, 2019
Deloitte and Tisch Multiple Sclerosis Research Center of New York Leverage AI, Data Science to Help Accelerate MS Research in the 'Age of With(TM)'
Nov 12, 2019
Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY(TM)
Nov 07, 2019
Mallinckrodt Announces Data Publication on the Treatment Effectiveness of Acthar® Gel (Repository Corticotropin Injection) for Resolution of Multiple Sclerosis Relapse in a U.S. Health Plan Population
Nov 07, 2019
Immunic, Inc. Reports Third Quarter 2019 Financial Results and Highlights Recent Activity
Oct 31, 2019
Pharmascience Inc. launches pms-FINGOLIMOD for the treatment of relapsing-remitting multiple sclerosis (MS) in adults
Oct 31, 2019
Teva Canada Announces the Launch of a Bioequivalent Generic Version of [Pr]Gilenya®, [Pr]Teva-Fingolimod Capsules for the treatment of Relapsing-Remitting Multiple Sclerosis (MS)
Oct 23, 2019
Multiple Sclerosis Association of America and Novartis Join Forces with TV Personality Montel Williams to Heighten Awareness of MS Progression through Storytelling
Oct 10, 2019
Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
Oct 07, 2019
Benefitting From Expanded Access in Europe, Roche's Ocrevus is on Track to Displace Biogen's Tysabri in Neurologist Preference and Share Among Patients with Relapsing Forms of Multiple Sclerosis Over the Next Six Months
Oct 03, 2019
MS Survey Finds Positive HCP Relationships, Proactive Medication Interest Likely Indicators of DMT Use
Oct 01, 2019
Mallinckrodt Announces Positive Top-Line Findings from its Observational Registry Assessing Relapse Recovery in Multiple Sclerosis Relapse Patients Treated with Acthar® Gel (Repository Corticotropin Injection)